Mps Pharmaa Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of MPS Pharmaa Ltd is ₹ 1.73 as of 27 Apr 15:30 . The P/E Ratio of MPS Pharmaa Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Vaishali Pharma Ltd changed from 32.9 on March 2021 to 209.7 on March 2025 . This represents a CAGR of 44.84% over 5 years The Market Cap of MPS Pharmaa Ltd changed from ₹ 1.43 crore on March 2021 to ₹ 6.08 crore on March 2025 . This represents a CAGR of 33.57% over 5 yearsThe Market Cap of Vaishali Pharma Ltd changed from ₹ 171.9 crore on March 2021 to ₹ 134.85 crore on March 2025 . This represents a CAGR of -4.74% over 5 years The Revenue of MPS Pharmaa Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of MPS Pharmaa Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of MPS Pharmaa Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of MPS Pharmaa Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About MPS Pharmaa Ltd

MPS Pharmaa Limited (Formerly known Advik Laboratories Limited) was incorporated in September, 1994.
The Company was promoted in by the Jains along with a group of dedicated professionals.
Presently, it is engaged in the manufacture and sale of pharmaceutical products in India.
It offers ethical, generic, and over the counter drugs in various formulations.
The company's generic product portfolio comprises antibacterial; antiallergics; antifungals; analgesic, antipyretic, and anti-inflammatory; antihypertensives; anthelminthics; antimalarials; corticosteroids; erectile dysfunction; gastrointestinal agents; sedatives; and other miscellaneous products. The company commenced commercial production in 1997.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of MPS Pharmaa Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, MPS Pharmaa Ltd or Vaishali Pharma Ltd?

Market cap of MPS Pharmaa Ltd is 3 Cr while Market cap of Vaishali Pharma Ltd is 96 Cr

What are the key factors driving the stock performance of MPS Pharmaa Ltd and Vaishali Pharma Ltd?

The stock performance of MPS Pharmaa Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for MPS Pharmaa Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the MPS Pharmaa Ltd stock price is INR ₹1.73. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.43.

How do dividend payouts of MPS Pharmaa Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of MPS Pharmaa Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.